

Giacomo Zaccherini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3937185/publications.pdf>

Version: 2024-02-01

63
papers

6,684
citations

257357

24
h-index

161767

54
g-index

64
all docs

64
docs citations

64
times ranked

4979
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 1100-1112.	2.0	5
2	Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2021, 74, 330-339.	1.8	76
3	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
4	Assessing the role of amino acids in systemic inflammation and organ failure in patients with ACLF. <i>Journal of Hepatology</i> , 2021, 74, 1117-1131.	1.8	45
5	On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites. <i>Journal of Hepatology</i> , 2021, 74, 340-349.	1.8	38
6	Endpoints and design of clinical trials in patients with decompensated cirrhosis: Position paper of the LiverHope Consortium. <i>Journal of Hepatology</i> , 2021, 74, 200-219.	1.8	16
7	Acute-on-chronic liver failure: Definitions, pathophysiology and principles of treatment. <i>JHEP Reports</i> , 2021, 3, 100176.	2.6	84
8	Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications. <i>Hepatology</i> , 2021, 74, 2058-2073.	3.6	45
9	The Use of Rifaximin in Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 1660-1673.	3.6	67
10	009â€¦A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. , 2021, , .		5
11	Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. <i>Journal of Clinical Medicine</i> , 2021, 10, 4590.	1.0	4
12	Management of Ascites in Patients with Cirrhosis: An Update. <i>Journal of Clinical Medicine</i> , 2021, 10, 5226.	1.0	14
13	Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 31-41.	3.7	75
14	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	1.8	223
15	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
16	Prognostic Role of Bacterial and Fungal Infections in Patients With Liver Cirrhosis With and Without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa453.	0.4	7
17	Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2020, 73, S211-S212.	1.8	0
18	Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment. <i>Journal of Hepatology</i> , 2020, 73, S738.	1.8	0

#	ARTICLE	IF	CITATIONS
19	<p>Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: A Systematic Review of the Literature</p>. Hepatic Medicine: Evidence and Research, 2020, Volume 12, 153-172.	0.9	15
20	A web-based group treatment for patients with alcoholic liver diseases at the time of the COVID-19 pandemic. Digestive and Liver Disease, 2020, 52, 956-957.	0.4	7
21	Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease. Current Hepatology Reports, 2020, 19, 147-158.	0.4	7
22	Albumin: Indications in chronic liver disease. United European Gastroenterology Journal, 2020, 8, 528-535.	1.6	9
23	Long-term albumin therapy is not futile in patients with cirrhosis and uncomplicated ascites not normalizing on-treatment serum albumin concentration. Digestive and Liver Disease, 2020, 52, e57-e58.	0.4	1
24	Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. JHEP Reports, 2019, 1, 270-277.	2.6	12
25	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	1.0	2
26	PS-083-Serum albumin concentration as guide for long-term albumin treatment in patients with cirrhosis and uncomplicated ascites: Lessons from the ANSWER study. Journal of Hepatology, 2019, 70, e53.	1.8	5
27	The Analysis of Food Intake in Patients with Cirrhosis Waiting for Liver Transplantation: A Neglected Step in the Nutritional Assessment. Nutrients, 2019, 11, 2462.	1.7	16
28	The residual native albumin predicts albumin dysfunction and outcomes in hospitalized cirrhotic patients with acute decompensation or acute-on-chronic liver failure. Digestive and Liver Disease, 2019, 51, e41.	0.4	1
29	PS-102-Circulating native albumin in patients with cirrhosis admitted to hospital for acute decompensation and acute-on-chronic liver failure: Relation to serum albumin levels, albumin function, and patient outcomes. Journal of Hepatology, 2019, 70, e65.	1.8	0
30	SAT-152-Prediction of nosocomial acute-on-chronic liver failure in patients with cirrhosis admitted to hospital with acute decompensation. Journal of Hepatology, 2019, 70, e698.	1.8	0
31	Hospital Care of Older Patients With COPD: Adherence to International Guidelines for Use of Inhaled Bronchodilators and Corticosteroids. Journal of the American Medical Directors Association, 2019, 20, 1313-1317.e9.	1.2	5
32	Long-term albumin administration in patients with cirrhosis and uncomplicated ascites: the use of serum albumin concentration for personalizing treatment. Digestive and Liver Disease, 2019, 51, e9.	0.4	2
33	Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide. Gastroenterology, 2019, 156, 1368-1380.e10.	0.6	296
34	Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. European Journal of Internal Medicine, 2019, 61, 54-61.	1.0	52
35	Pro: The Role of Albumin in Pre"Liver Transplant Management. Liver Transplantation, 2019, 25, 128-134.	1.3	9
36	Low Adherence To Nutritional Recommendations In Patients With Cirrhosis: A Prospective Observational Study. Journal of Gastroenterology and Hepatology Research, 2019, 8, 2896-2902.	0.2	4

#	ARTICLE	IF	CITATIONS
37	Prolonged albumin administration in patients with decompensated cirrhosis: the amount makes the difference. <i>Annals of Translational Medicine</i> , 2019, 7, S201-S201.	0.7	4
38	Bacterial infections with and without acute-on-chronic liver failure in patients with cirrhosis and acute decompensation: Risk factors and outcome. <i>Digestive and Liver Disease</i> , 2018, 50, 10.	0.4	1
39	Choice and Outcomes of Rate Control versus Rhythm Control in Elderly Patients with Atrial Fibrillation: A Report from the REPOSI Study. <i>Drugs and Aging</i> , 2018, 35, 365-373.	1.3	17
40	Approach and management of dysnatremias in cirrhosis. <i>Hepatology International</i> , 2018, 12, 487-499.	1.9	14
41	Polypharmacy in older people: lessons from 10 years of experience with the REPOSI register. <i>Internal and Emergency Medicine</i> , 2018, 13, 1191-1200.	1.0	45
42	Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. <i>Lancet</i> , 2018, 391, 2417-2429.	6.3	345
43	Outcome of bacterial infections complicated or not by acute-on-chronic liver failure in patients with cirrhosis admitted to hospital for acute decompensation. <i>Journal of Hepatology</i> , 2018, 68, S248.	1.8	0
44	A Case of Immune-Mediated Liver Injury Induced by Olaparib. <i>Hepatology</i> , 2018, 68, 2039-2041.	3.6	3
45	Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POLiterapie Societ� Italiana di Medicina) Tj ETQq1 1 0.384314 ogBT /Ov		
46	Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure. <i>Hepatology</i> , 2016, 64, 1249-1264.	3.6	550
47	Clinical Course of acute-on-chronic liver failure syndrome and effects on prognosis. <i>Hepatology</i> , 2015, 62, 243-252.	3.6	493
48	The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, 831-840.	1.8	289
49	Long-term use of human albumin for the treatment of ascites in patients with hepatic cirrhosis: The interim analysis of the ANSWER study. <i>Digestive and Liver Disease</i> , 2015, 47, e6.	0.4	3
50	Role of Human Albumin in the Management of Complications of Liver Cirrhosis. <i>Journal of Clinical and Experimental Hepatology</i> , 2014, 4, 302-311.	0.4	84
51	Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. <i>Journal of Hepatology</i> , 2014, 61, 1038-1047.	1.8	741
52	Acute-on-Chronic Liver Failure Is a Distinct Syndrome That Develops in Patients With Acute Decompensation of Cirrhosis. <i>Gastroenterology</i> , 2013, 144, 1426-1437.e9.	0.6	2,211
53	A case of pneumonia and sepsis in cirrhosis as paradigm of the problems in the management of bacterial infections in cirrhosis and of the limitations of current knowledge. <i>Italian Journal of Medicine</i> , 2013, , 209-214.	0.2	0
54	A look at the hepatic encephalopathy in cirrhosis. <i>Reviews in Health Care</i> , 2013, 4, 55-74.	0.1	0

#	ARTICLE	IF	CITATIONS
55	The use of albumin in the complications of cirrhosis: evidence and future perspectives. <i>Reviews in Health Care</i> , 2013, 4, 159-173.	0.1	0
56	Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis. <i>Laboratory Investigation</i> , 2012, 92, 384-395.	1.7	51
57	QT interval prolongation in liver cirrhosis: innocent bystander or serious threat?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2012, 6, 57-66.	1.4	86
58	Human albumin in the management of complications of liver cirrhosis. <i>Critical Care</i> , 2012, 16, 211.	2.5	63
59	Hyposplenism as a cause of pneumococcal meningoenzephalitis in an adult patient with coeliac disease. <i>Italian Journal of Medicine</i> , 2011, 5, 124-127.	0.2	1
60	A Case of Prolonged Cholestatic Hepatitis Induced by Azithromycin in a Young Woman. <i>Case Reports in Hepatology</i> , 2011, 2011, 1-4.	0.4	7
61	How albumin administration for cirrhosis impacts on hospital albumin consumption and expenditure. <i>World Journal of Gastroenterology</i> , 2011, 17, 3479.	1.4	26
62	Bacterial infections in patients with liver cirrhosis. <i>Reviews in Health Care</i> , 2011, 2, 147-159.	0.1	0
63	Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. <i>Atherosclerosis</i> , 2010, 208, 222-227.	0.4	61